Expression of p21(WAF1/CIP1) in colorectal adenomas and adenocarcinomas and its correlation with p53 protein expression

Pathology International

Volumn 47, Issue 7, 1997, Pages 470-477

  Yasui, Wataru ^a   Akama, Yoshihiko ^a   Yokozaki, Hiroshi ^a   Semba, Shuho ^a   Kudo, Yasusei ^a   Shimamoto, Fumio ^b   Tahara, Eiichi ^a  

^a HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

^b HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Colorectal adenocarcinoma; Colorectal adenoma; Immunohistochemistry; P21(WAF1 CIP1); P53; Western blotting

Indexed keywords

PROTEIN P21; PROTEIN P53; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; ENZYME INHIBITOR; KI 67 ANTIGEN;

ARTICLE; CANCER GROWTH; CANCER INCIDENCE; COLON ADENOCARCINOMA; COLON ADENOMA; COLON MUCOSA; COLORECTAL CARCINOMA; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RECTUM ADENOMA; RECTUM MUCOSA; ADENOCARCINOMA; ADENOMA; COLORECTAL TUMOR; INTESTINE MUCOSA; METABOLISM; WESTERN BLOTTING;

ADENOCARCINOMA; ADENOMA; BLOTTING, WESTERN; COLORECTAL NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; ENZYME INHIBITORS; HUMANS; IMMUNOHISTOCHEMISTRY; INTESTINAL MUCOSA; KI-67 ANTIGEN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030611832     PISSN: 13205463     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1827.1997.tb04526.x     Document Type: Article

References (38)

1. Tahara E. Genetic alterations in human gastrointestinal cancers: The application to molecular diagnosis. Cancer 1995; 75 (Suppl.): S1410-1417.
2. Sherr CJ. G1 phase progression: Cycling on cue. Cell 1994; 79: 515-555.
3. Hunter T, Pines J. Cyclins and cancer II: Cyclin D and CDK inhibitors come of age. Cell 1994; 79: 573-582.
4. El-Deiry WS, Tokino T, Velculescu VE et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-825.
5. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993; 75: 805-816.
6. KIP1, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Gene Dev. 1994; 8: 9-22.
7. Toyoshima H, Hunter T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 1994; 78: 67-74.
8. Kamb A, Gruis NA, Weavere-Feldhaus J et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994; 264: 436-440.
9. INK4B is a potent effector of TGF-β-induced cell cycle arrest. Nature 1994; 371: 257-261.
10. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994; 368:753-756.
11. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993; 366: 704-707.
12. Liu Q, Neuhausen S, McClure M et al. CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines. Oncogene 1995; 10: 1061-1067.
13. Xiong Y, Hannon G, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993; 366: 701-704.
14. Waga S, Hannon GJ, Beach D, Stillman B. The p21 inhibitor of cyclin-dependent kinase controls DNA replication by interaction with PCNA. Nature 1994; 369: 574-576.
15. Noda A, Ning Y, Benable SF, Pereira-Smith OM, Smith JR. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp. Cell Res. 1994; 211: 90-98.
16. Shiohara M, El-Deiry WS, Wada M et al. Absence of WAF1 mutations in a variety of human malignancies. Blood 1994; 84: 3781-3784.
17. 21SDI1/WAF1/CIP1/MDA6 gene jn human gastric carcinomas. Mol. Cell. Differ. 1996; 4: 187-198.
18. Ayhan A, Yasui W, Yokozaki H, Ito H, Tahara E. Genetic abnormalities and expression of p53 in human colon carcinomas. Int. J. Oncol. 1992; 1: 431-437.
19. Akama Y, Yasui W, Kuniyasu H et al. Genetic status and expression of the cyclin-dependent kinase inhibitors in human gastric carcinoma cell lines. Jpn. J. Cancer Res. 1996; 87: 824-830.
20. WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res. 1995; 55: 2910-2919.
21. WAF1/CIP1 is heterogenous and unrelated to proliferation index in human ovarian carcinoma. Int. J. Cancer 1995; 63: 611-615.
22. DiGiuseppe JA, Redston MS, Yeo CJ, Kern SE, Hruban RH. p53-independent expression of the cyclin-dependent kinase inhibitor p21 in pancreatic carcinoma. Am. J. Pathol. 1995; 147: 884-888.
23. Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE, Givol D. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res. 1994; 54: 3391-3395.
24. Zhang W, Grasso L, McClain CD et al. p53-independent induction of WAF1/CIP1 in human leukemia cells is correlated with growth arrest accompanying monocyte/macrophage differentiation. Cancer Res. 1995; 55: 668-674.
25. Akagi M, Yasui W, Akama Y et al. Inhibition of cell growth by transforming growth factor β1 is associated with p53-independent induction of p21 in gastric carcinoma cell lines. Jpn. J. Cancer Res. 1996; 87: 377-384.
26. General Rules for Clinical and Pathological Studies on Cancer of the Colon, Rectum and Anus. Japanese Research Society for Cancer of the Colon and Rectum. 5th edn. Kanehara, Tokyo, 1994.
27. Yasui W, Ji Z-Q, Kuniyasu H et al. Expression of transforming growth factor alpha in human tissues: Immunohistochemical study and Northern blot analysis. Virchows Arch. A Pathol. Anat. Histopathol. 1992; 421: 513-519.
28. cdc2 and its kinase activity in human gastric and colonic carcinomas, Int. J. Cancer 1993; 53: 36-41.
29. Weidner N, Moore DH, Vartanian R. Correlation of Ki-67 antigen expression with mitotic figure index and tumor grade in breast carcinomas using the novel 'paraffin'-reactive MIB1 antibody. Hum. Pathol. 1994; 25: 337-342.
30. 1/S cell cycle mediators in cellular senescence. Exp. Cell Res. 1993; 209: 231-237.
31. CIP1 in muscle and other terminally differentiating cells. Science 1995; 267: 1024-1027.
32. CWAF1/CLP1 in non-neoplastic mucosa and neoplasia of the stomach: Relation with p53 status and proliferative activity. J. Pathol. 1996; 180: 122-128.
33. Akama Y, Yasui W, Yokozaki H et al. Frequent amplification of the cyclin E gene in human gastric carcinomas. Jpn. J. Cancer Res. 1995; 86: 617-621.
34. Yasui W, Akama Y, Kuniyasu H, Yokozaki H, Shimamoto F, Tahara E. Expression of cyclin E in human gastric adenomas and adenocarcinomas: Correlation with proliferative activity and p53 status. J. Exp. Ther. Oncol. 1996; 1: 88-94.
35. Yasui W, Kuniyasu H, Yokozaki H, Semba S, Shimamoto F, Tahara E. Expression of cyclin E in colorectal adenomas and adenocarcinomas: Correlation with expression of Ki-67 and p53 protein. Virchows Archiv. 1996; 429: 13-19.
36. Yokozaki H, Kuniyasu H, Kitadai Y et al. p53 point mutations in primary human gastric carcinomas. J. Cancer Res. Clin. Oncol. 1992; 119: 67-70.
37. Elbendary A, Berchuck A, Davis P et al. Transforming growth factor β1 can induce CIP1/WAF1 expression independent of the p53 pathway in ovarian cancer cells. Cell Growth Differ. 1994; 5: 1301-1307.
38. Merlo A, Herman JG, Lee DJ et al. 5′ CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancers. Nature Med. 1995; 1: 686-692.